Biogen Inc. (BIIB) Discusses Proposed Acquisition of Apellis and Strategic Growth Objectives Transcript
Biogen Inc. (BIIB) Discusses Proposed Acquisition of Apellis and Strategic Growth Objectives Transcript
Fiscal Year: January - December
Biogen Inc. (BIIB), listed on the NASDAQ, has a market capitalization of $26.03B. As of Apr 05, 2026, the stock is trading at $177.34 per share@else an unavailable price , offering investors a clear view of its current market value. Biogen Inc. is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 20.18, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Biogen Inc. also offers a dividend yield of N/A , making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Biogen Inc. (BIIB) may be undervalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for Biogen Inc. is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Biogen Inc., Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Biogen Inc. is 12.69, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Biogen Inc. (BIIB) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Biogen Inc. (BIIB) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be undervalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Biogen Inc. (BIIB) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Biogen Inc.. To access the full SS Score, consider upgrading your subscription.
Biogen Inc. is a significant player in the industry sector, with a market capitalization of $26.03B and a competitive P/E ratio of 20.18. Investors should compare these metrics with industry peers to gauge whether Biogen Inc. is outperforming or underperforming within its sector.
Biogen Inc. (BIIB) Discusses Proposed Acquisition of Apellis and Strategic Growth Objectives Transcript
A small biopharmaceutical firm was getting a big boost Tuesday after Biogen agreed to buy it for $5.6 billion.
Biogen, already developing a drug that can be used to treat several kidney disorders, is paying a large premium for Apellis Pharmaceuticals
Biogen agreed to acquire Apellis Pharmaceuticals for approximately $5.6 billion, expanding its portfolio in immunology and rare-disease medicines.
Biogen said on Tuesday it has agreed to acquire Apellis Pharmaceuticals for about $5.6 billion in cash.
CAMBRIDGE, Mass. and WALTHAM, Mass., March 31, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced the companies have entered into a de...
CAMBRIDGE, Mass. and WALTHAM, Mass., March 31, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced the companies have entered into a de...
• Biogen stock is moving in positive territory. Why is BIIB stock advancing?
The U.S. Food and Drug Administration has approved a higher-dose version of Biogen's drug for a rare genetic disorder that causes progressive muscle weakness, offering patients a potentiall...
The approval was anchored on data from the pivotal DEVOTE study that investigated the efficacy and safety of the High Dose Regimen of SPINRAZA in treatment-naïve and previously treated SPINRAZA patien...
CAMBRIDGE, Mass., March 28, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced positive results from the Phase 2 part of the AMETHYST Phase 2/3 study (Part A) of litifilimab in people livin...
- Biogen gains rights to develop and commercialize subcutaneous (SC) formulations for two products utilizing ALT-B4 DAEJEON, South Korea, March 25, 2026 /PRNewswire/ -- Alteogen Inc. (KOSDAQ: 196170) ...
Real-World LEQEMBI Data Shows Patients Choose to Stay on Long-Term Treatment Real-World LEQEMBI Data Shows Patients Choose to Stay on Long-Term Treatment
CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 2026 American Academy of Dermatology (AAD) Annual Meeting, taki...
Biogen Inc. (BIIB) Presents at Stifel 2026 Virtual CNS Forum Transcript
New Phase 1b data support the safety and effectiveness of salanersen over one year in children with SMA who had the potential for improvement due to suboptimal clinical status with prior gene therapy ...
Biogen Inc. (BIIB) Presents at Leerink Global Healthcare Conference 2026 Transcript
Long-term data from DEVOTE/ONWARD studies show benefits of high dose nusinersen in people living with spinal muscular atrophy (SMA) New Phase 1b data further illustrate potential of salanersen in SMA,...
BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with R...
Biogen Inc. (BIIB) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Biogen Inc. (BIIB) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript
Caroline Dorsa to retire from the Biogen Board of Directors; Dr. Maria C. Freire, Director since 2021, elected as new Chair Caroline Dorsa to retire from the Biogen Board of Directors; Dr. Maria C. Fr...
Biogen Inc. (NASDAQ: BIIB) on Friday reported better-than-expected fourth-quarter earnings.
Biogen (BIIB) is transitioning from a shrinking MS franchise to a portfolio anchored in rare disease and Alzheimer's therapies, driving improved mix quality. BIIB's 2025 growth products generated $3.3...
Biogen Inc. (BIIB) Q4 2025 Earnings Call Transcript
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | # Analysts |
|---|---|---|---|
| 2025 | 2.64B | -2.98% | Est @-3.0% |
| 2026 | 2.56B | -3.07% | Analyst x4 |
| 2027 | 2.51B | -1.84% | Analyst x4 |
| 2028 | 2.67B | 6.45% | Analyst x4 |
| 2029 | 2.55B | -4.75% | Analyst x3 |
| 2030 | 2.59B | 1.79% | Analyst x3 |
| 2031 | 2.62B | 1.00% | Est @1.0% |
| 2032 | 2.66B | 1.47% | Est @1.5% |
| 2033 | 2.71B | 1.79% | Est @1.8% |
| 2034 | 2.76B | 1.89% | Est @1.9% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2023A | 1.27B | 1.00 | 1.27B |
| 2024A | 2.72B | 1.00 | 2.72B |
| 2025E | 2.64B | 1.07 | 2.46B |
| 2026E | 2.56B | 1.15 | 2.22B |
| 2027E | 2.51B | 1.24 | 2.03B |
| 2028E | 2.67B | 1.33 | 2.02B |
| 2029E | 2.55B | 1.42 | 1.79B |
| 2030E | 2.59B | 1.53 | 1.70B |
| 2031E | 2.62B | 1.64 | 1.60B |
| 2032E | 2.66B | 1.76 | 1.51B |
| 2033E | 2.71B | 1.89 | 1.43B |
| 2034E | 2.76B | 2.03 | 1.36B |
| Terminal | 58.72B | 2.03 | 28.99B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.